{
    "nct_id": "NCT04154943",
    "official_title": "A Phase 2 Study of Neoadjuvant Cemiplimab for Stage II to IV (M0) Cutaneous Squamous Cell Carcinoma (CSCC)",
    "inclusion_criteria": "Key Inclusion Criteria\n\n* Stage II to IV (M0) CSCC, for which surgery would be recommended in routine clinical practice. For stage II patients, lesion must be â‰¥3 cm at the longest diameter.\n* At least 1 lesion that is measurable by RECIST 1.1\n* Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1\n* Adequate organ, bone marrow function, and hepatic function as defined in the protocol\n\nKey Exclusion Criteria\n\n* Solid malignancy within 5 years of the projected enrollment date, or hematologic malignancy (including chronic lymphocytic leukemia [CLL]) at any time\n* Distant metastatic disease (M1), visceral and/or distant nodal\n* Prior radiation therapy for CSCC\n* Patients with a condition requiring corticosteroid therapy (>10 mg prednisone/day or equivalent) within 14 days of the first dose of study drug.\n* Patients with active, known, or suspected autoimmune disease that has required systemic therapy within 5 years of the projected enrollment date.\n* History of interstitial lung disease (eg, idiopathic pulmonary fibrosis, organizing pneumonia) or active, noninfectious pneumonitis that required immune-suppressive doses of glucocorticoids to assist with management.\n* Uncontrolled infection with human immunodeficiency virus (HIV), hepatitis B or hepatitis C virus (HBV or HCV) infection; or diagnosis of immunodeficiency\n* Active tuberculosis\n\nNOTE: Other protocol-defined Inclusion/Exclusion Criteria apply\nHealthy volunteers allowed\nMust have minimum age of 18 Years",
    "exclusion_criteria": "",
    "miscellaneous_criteria": ""
}